Document is current
Any future updates will be listed below
-
Authors
Bozorgmehr, Farastuk http://orcid.org/0000-0001-8058-8884
Hommertgen, Adriane
Krisam, Johannes
Lasitschka, Felix
Kuon, Jonas
Maenz, Martin
Huber, Peter E.
König, Laila
Kieser, Meinhard
Debus, Juergen
Thomas, Michael
Rieken, Stefan
-
Funding
Funding for this research was provided by:
Bristol-Myers Squib (CA209-430)
Federal Ministry of Education and Research (NCT3.0)
- License Information
-
More Information
Article History
Received: 30 October 2018
Accepted: 25 September 2019
First Online: 8 November 2019
Ethics approval and consent to participate
: Ethical approval by the Ethics Committee of the Medical Faculty of the University of Heidelberg was obtained (AFmu-339/2016 / 02 December 2016). Written informed consent is obtained from all participants. Furthermore, the DEGRO expert panel reviewed the radiation regimen to rule out that permission of radiation administered would have to be requested from the BfS (Federal office of radiation protection; “Anfrage 98 / 16 July2015”). Additionally, the Paul Ehrlich Institute (competent authority for approval of clinical trials using medicinal products for human use in Germany) approved the study (no. 2828/01, 31 October 2016).
: Not applicable – as no individual patient data are contained in this manuscript.
: The FORCE trial received funding from Bristol-Myers Squibb GmbH & Co.KGaA (BMS). BMS has not been involved in the study design, and has no role in data collection, management, data analysis and interpretation, or in the decision to submit this protocol for publication.All authors declare that there are no competing conflicts of interest.
